Outcome (studies)
Improvement
Relative risk · 95% CI
00.511.5+
← Ensifentrine
reduces riskIncreased
risk →
reduces riskIncreased
risk →
Ensifentrine for COVID-19
1
study with
45
patients
Serious outcome risk
No significant improvements are seen in meta-analysis to date.
COVID-19 Ensifentrine studies · November 2026
|
Outcome (studies)
Improvement
Relative risk · 95% CI
00.511.5+
← Ensifentrine
reduces riskIncreased risk → |
May 1 2021 |
et al., NCT04527471 | A Single-center, Pilot, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ensifentrine in the Recovery of Hospitalized Patients With COVID-19 |
| 150% higher mortality (p=1) and 150% worse recovery (p=1). RCT 45 hospitalized COVID-19 patients showing no significant difference with ensifentrine treatment. | ||
